Amarin Corp Plc (AMRN)

[north40000]

3) GILD might fit your item 3). Vascepa would complement its anti-inflammatory pipeline nicely, and lack of completion of Phase 3 results has not been an inhibiting factor in the past.

OTOH, in light of recent posts by others here, AZN fits the bill too for a partnership/acquisition. It entered a collaboration with PPHM within the past year(durvalumab?) in an immuno-therapy/oncology setting, combining with Bavituximab then in a phase 3 chemo-therapy trial. That last study is ongoing, with some top- line results to be presented at ESMO in early October.